Financial News · Live Terminal

Page 1519 of 2499

Profound Medical Down 8.5% After Hours as Its Q1 Loss Narrows, Revenue More Than Doubles, Beats Estimates

Profound Medical (PRN.TO, PROF) was last seen down 8.5%% in after-hours New York trade after the company on Thursday reported a narrower first-quarter loss as revenue advanced, with both measures beating forecasts.The medical-device company said it lost US$7.0 million, or US$0.19 per share, in the quarter, compared to a loss of US$10.7 million, or US$0.36, in the prior year period. Analysts polled by FactSet had expected a loss of US$0.25 per share.Revenue jumped 104% to US$5.3 million over the same period, beating the US$4.9 million FactSet forecast. The company said it earned US$2.5 million revenue from recurring non-capital revenue, which consists of the sale of one-time use devices and services associated with extended warranties, and US$2.9 million from the one-time sale of capital equipment.The company projects total revenue for full-year 2026 to be approximately US$25 million, which represents 56% growth compared to its prior year revenue. The company also expects full year 2026 gross margin to be 70% or higher.Profound said its Profound's TULSA-PRO installed base stood at 80 at the end of Q1-2026, and the company shipped an additional six systems during the first quarter that had yet to be installed. It also announced that Humana has become the first national payor in the United States to cover the TULSA Procedure."We continued to execute well across our business in the first quarter, delivering triple-digit revenue growth combined with strong gross margin and lower operating expenses. We were also pleased to see statistically significant and clinically meaningful benefit from the TULSA Procedure beginning to readout from the randomized post-market CAPTAIN clinical trial comparing it to robotic radical prostatectomy, the current standard of care," said chief executive Arun Menawat.The company's shares were down US$0.61 to US$6.55 after hours trading after closing up C$0.14 to $9.75 on the Toronto Stock Exchange.

$PRN.TO$PROF

Insider Trading55d ago

Datadog Insider Sold Shares Worth $287,100, According to a Recent SEC Filing

Sean Michael Walters, Chief Revenue Officer, on May 05, 2026, sold 1,914 shares in Datadog (DDOG) for $287,100. Following the Form 4 filing with the SEC, Walters has control over a total of 291,275 Class A common shares of the company, with 291,267 shares held directly and 8 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1561550/000156155026000132/xslF345X05/wk-form4_1778185864.xml

$DDOG

Insider Trading55d ago

United Therapeutics Insider Sold Shares Worth $5,600,468, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on May 06, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,600,468. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,797 common shares of the company, with 40,513 shares held directly and 639,284 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000048/xslF345X05/primarydocument.xml

$UTHR

Insider Trading55d ago

United Therapeutics Insider Sold Shares Worth $4,870,054, According to a Recent SEC Filing

Paul A Mahon, Executive Vice President & General Counsel, on May 07, 2026, sold 8,300 shares in United Therapeutics (UTHR) for $4,870,054. Following the Form 4 filing with the SEC, Mahon has control over a total of 45,172 common shares of the company, with 45,172 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000123158926000011/xslF345X05/primarydocument.xml

$UTHR

Research55d ago

Research Alert: Oln Q1: Q1 Loss Widens On Chlor Alkali Weakness; Q2 Recovery Expected

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Olin reported a net loss of $83.0M, or -$0.73 per share vs. net income of $1.4M, or $0.01 per share, in Q1 2025, with sales declining 3.7% to $1,583.0M and adjusted EBITDA falling to $86.2M from $185.6M. The Chlor Alkali segment posted a $44.5M loss vs. $78.3M earnings due to lower pricing/volumes and higher costs, while Winchester sales rose 21.3% to $470.5M, though segment earnings declined. We believe the company is navigating challenging market conditions through its Beyond250 cost reduction program and sequential EBITDA improvement from Q4 2025. Management provided Q2 2026 adjusted EBITDA guidance of $160M-$200M, reflecting expected sequential improvement from seasonally higher demand and pricing gains. We expect the Iran conflict to benefit North American operations through supply disruptions, while net debt/EBITDA increased to 5.1x from 3.5x, though the company maintained $1.3B liquidity and declared its 398th consecutive quarterly dividend of $0.20 per share.

$OLN

Research55d ago

Research Alert: CFRA Reiterates Strong Sell On Shares Of Polestar Automotive Holding Uk Plc

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We maintain a 12-month target of $5, based on our DCF analysis and implying a premium to tangible book value. After updating our estimates and adjusting for its recent equity and debt-to-equity transactions, our adjusted EPS estimates decline to -$12.30 from -$0.55 for 2026 and to -$9.30 from -$0.45 for 2027. PSNY posted Q1 net income of -$383M, down from -$166M in Q1 2025. Revenue was flat at $633M ($116M below consensus) as lower prices offset a 7% increase in total vehicle sales to 13,126 units. Adjusted EBITDA of -$235M was down from -$96M a year ago. In our view, risks surrounding PSNY remain high. Like other upstart EV manufacturers, we think the primary challenge it faces is achieving the size and scale to compete with larger automakers, noting the number of measures it has recently taken to secure additional liquidity and its significant cash burn. Moreover, we think it could be challenged to hit its 2026 vehicle sales guidance, namely a low double-digit increase over 2025 sales of 60,119 vehicles.

$PSNY

Wire55d ago

Applied Optoelectronics Q1 Non-GAAP Loss Widens, Revenue Rises; Sets Q2 Guidance

Applied Optoelectronics (AAOI) reported a Q1 non-GAAP net loss late Thursday of $0.07 per diluted share, widening from a loss of $0.02 a year earlier.Analysts polled by FactSet expected a loss of $0.05.Revenue for the quarter that ended March 31 was $151.1 million, up from $99.9 million a year earlier.Analysts surveyed by FactSet expected $157 million.The company expects Q2 non-GAAP range to be a loss per share of $0.03 to EPS of $0.03 on revenue of $180 million to $198 million. Analysts expect EPS of $0.07 and revenue of $196.7 million.

$AAOI

Wire55d ago

HubSpot Q1 Adjusted Earnings, Revenue Rise; Shares Fall After Hours

HubSpot (HUBS) reported Q1 adjusted earnings late Thursday of $2.72 per diluted share, up from $1.78 a year earlier.Analysts polled by FactSet expected $2.47.Revenue in the three months ended March 31 rose to $881 million from $714.1 million a year earlier.Analysts surveyed by FactSet expected $863.3 million.HubSpot expects Q2 non-GAAP net income of $3 to $3.02 a share on revenue of $897 million to $898 million.Analysts polled by FactSet expect EPS of $2.86 on revenue of $899.5 million.The company boosted guidance for full-year non-GAAP net income to $13.04 to $13.12 a share on revenue of $3.70 billion to $3.708 billion. The prior outlook was EPS of $12.38 to $12.46 on revenue of $3.69 billion to $3.70 billionAnalysts polled by FactSet expect EPS of $12.45 on revenue of $3.7 billion.HubSpot shares fell 11% in after-hours trading.

$HUBS

Insider Trading55d ago

Alexandria Real Estate Equities Insider Bought Shares Worth $347,558, According to a Recent SEC Filing

Joel S Marcus, Director, Executive Chairman, on May 06, 2026, executed a purchase for 7,500 shares in Alexandria Real Estate Equities (ARE) for $347,558. Following the Form 4 filing with the SEC, Marcus has control over a total of 587,724 common shares of the company, with 587,724 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1035443/000121695526000017/xslF345X05/wk-form4_1778185919.xml

$ARE

Insider Trading55d ago

Roblox Insider Sold Shares Worth $749,424, According to a Recent SEC Filing

Gregory Baszucki, Director, on May 05, 2026, sold 16,666 shares in Roblox (RBLX) for $749,424. Following the Form 4 filing with the SEC, Baszucki has control over a total of 10,718,343 Class A common shares of the company, with 10,346 shares held directly and 10,707,997 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1315098/000131509826000104/xslF345X05/wk-form4_1778185319.xml

$RBLX

Mining & Metals55d ago

Aritzia's Fiscal Q4 Adjusted Net Income, Net Revenue, Beat Estimatess

Aritzia's (ATZ.TO)fiscal fourth-quarter adjusted earnings and net revenue both jumped, beating estimates, the company said after trade on Thursday.Adjusted net income, stripped of most one-off items, jumped 41% in the quarter ended Mach 1 to $138.2 million, or $1.15 per share, from $98 million, or $0.83, in the prior year period. The consensus estimate among analysts polled by FactSet expected $1.03 per share.Net revenue climbed 33% to $1.19 billion over the same period, beating the $1.14 billion forecast, and above its own guidance of between $1.1 billion to $1.13 billion. Net revenue grew 38% in the U.S. and 24% in Canada. Comparable sales increased 27.7%, as all channels and all geographies generated positive double-digit growth, a statement said.For its fiscal first quarter, Aritzia expects net revenue to range between $900 million to $925 million, for 36% to 39% growth. SG&A as a percentage of net revenue is expected to decrease 50 bps to 100 bps from 33.5%. The company also noted that it achieved its Fiscal 2027 net revenue target of $3.5 billion to $3.8 billion one year early. It will update its next long-term strategic plan in the fall, chief executive Jennifer Wong said.Aritzia also renewed its normal-course issuer bid (NCIB) on May 5, to buy back up to 4.2 million of its subordinate voting shares. The NCIB will run from May 13 for one year.Aritzia shares closed down $6.09 to $142.00 on the Toronto Stock Exchange.

$ATZ.TO

Insider Trading55d ago

Avalo Therapeutics Insider Sold Shares Worth $1,513,673, According to a Recent SEC Filing

Paul Varki, Chief Legal Officer, on May 06, 2026, sold 75,063 shares in Avalo Therapeutics (AVTX) for $1,513,673. Following the Form 4 filing with the SEC, Varki has control over a total of 3,634 common shares of the company, with 3,634 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1534120/000167789626000004/xslF345X05/form4-05072026_080504.xml

$AVTX

Insider Trading55d ago

Aflac Insider Sold Shares Worth $737,308, According to a Recent SEC Filing

Charles D Lake II, Chairman & Representative Director, Aflac Life Insurance Japan, on May 05, 2026, sold 6,500 shares in Aflac (AFL) for $737,308. Following the Form 4 filing with the SEC, Lake has control over a total of 52,064 common shares of the company, with 50,737 shares held directly and 1,327 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/4977/000000497726000082/xslF345X05/wk-form4_1778184666.xml

$AFL

Research55d ago

Research Alert: CFRA Keeps Strong Buy View On Shares Of Kinaxis Inc. On Ebitda Margin Showing

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We maintain our Strong Buy (5-STARS) rating on KXS and increase our target price to CAD180 from CAD165. We maintain our earnings multiple of 28x and EBITDA multiple of 18x on FY 27 projections. We increase our FY 26 to $4.85 from $4.55 and our FY 27 to $5.02 from $4.77. Adjusted EBITDA margin expanded to 32% from 25% in the prior-year quarter, a 700-bp increase driven by gross margin expansion to 69% and operating expense leverage. Annual recurring revenue grew 20% to $447M, accelerating from 14% growth a year ago, as the company posted record Q1 new business bookings from large customer wins and existing account expansions. The combination of revenue growth acceleration and margin expansion drove profit to $29.4M (+85% Y/Y) with diluted EPS of $1.04 compared to $0.55 in Q1 2025. The cash flow story is unfolding as Q1 saw cash flows spent on buybacks total 63% of FY 25's total as shares begin to be more meaningfully reduced.

$KXS

Wire55d ago

Akamai Technologies Q1 Non-GAAP Earnings Fall, Revenue Rises; Q2 Guidance Set, 2026 Outlook Adjusted

Akamai Technologies (AKAM) reported Q1 non-GAAP net income late Thursday of $1.61 per diluted share, down from $1.70 a year earlier.Analysts polled by FactSet expected $1.60.Revenue for the three months ended March 31 rose to $1.07 billion from $1.02 billion a year earlier.Analysts surveyed by FactSet expected $1.07 billion.The company expects fiscal Q2 non-GAAP EPS of $1.45 to $1.65 on revenue of $1.08 billion to $1.10 billion. Analysts polled by FactSet expect $1.68 and $1.10 billion, respectively.For full year 2026, the company expects non-GAAP EPS of $6.40 to $7.15 on revenue of $4.45 billion to $4.55 billion, compared with previous EPS guidance of $6.20 to $7.20 on revenue of $4.40 billion to $4.55 billion.Analysts surveyed by FactSet expect $6.86 and $4.48 billion, respectively.

$AKAM

Insider Trading55d ago

Teva Pharmaceutical Industries Insider Sold Shares Worth $1,062,000, According to a Recent SEC Filing

Richard Daniell, Executive Vice President, Europe Commercial, on May 05, 2026, sold 30,000 shares in Teva Pharmaceutical Industries (TEVA) for $1,062,000. Following the Form 4 filing with the SEC, Daniell has control over a total of 55,755 ordinary shares of the company, with 55,755 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/818686/000119312526211833/xslF345X05/ownership.xml

$TEVA

Insider Trading55d ago

Teva Pharmaceutical Industries Insider Sold Shares Worth $384,444, According to a Recent SEC Filing

Amir Weiss, Chief Accounting Officer, on May 06, 2026, sold 10,679 shares in Teva Pharmaceutical Industries (TEVA) for $384,444. Following the Form 4 filing with the SEC, Weiss has control over a total of 20,016 ordinary shares of the company, with 20,016 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/818686/000119312526211855/xslF345X05/ownership.xml

$TEVA

Research55d ago

Research Alert: CFRA Maintains Buy Opinion On Shares Of Doordash, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our price target by $2 to $240, based on 30x our 2027 EPS view, just below DASH's three-year average (~32x) given competitive threats from AI and Uber Eats, offset by the company's dominant market position and positive network effects. We raise our 2026 adjusted EPS view by $0.10 to $5.63 and 2027's by $0.06 to $7.99. We are encouraged by DASH's Q2 Marketplace GOV guidance (+36% Y/Y), an encouraging result following relatively soft guidance for Q1, especially given fears of a weakening consumer. International sales continue to scale solidly, with Deliveroo accelerating to 14% Y/Y growth in Q1 vs. 7% growth in Q4 (we expect continued improvement all year). Margin pressure remains (adjusted EBITDA margin -20 bps Y/Y to 2.4%) but should fade as platform integration activities finish up early next year. Adjusted EBITDA guidance (midpoint of $820M) was above expectations ($742M), despite the company expecting another $50M gas relief charge, which should persist amid the Strait of Hormuz closure.

$DASH

Research55d ago

Research Alert: CFRA Keeps Buy Opinion On Shares Of Tyson Foods, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target remains $76, a 15x multiple of projected FY 27 EPS of $5.09 (raised by $0.02). We also lift our FY 26 (Sep.) EPS est. by $0.09 to $4.11. This multiple is slightly above TSN's long-term average of 14x, reflecting favorable secular tailwinds, including a continued shift in consumer preferences toward protein and improved earnings growth potential as the Beef segment recovers, likely in FY 27. Operationally, TSN is executing well, particularly in Chicken, where margins continue to widen, up 290 bps year over year in FQ2. Beef remains pressured by historically tight cattle supplies, with the U.S. herd at its lowest level since 1951, though we expect margins to improve following recent restructuring actions, including rightsizing production to improve capacity utilization. TSN's balance sheet is solid, noting its leverage ratio (net debt/adjusted EBITDA) has now improved to 2.2x vs. 3.9x two years ago. This provides a decent degree of financial flexibility in our view.

$TSN

Research55d ago

Research Alert: CFRA Lowers Rating On Shares Of Zoetis Inc. To Hold From Buy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $96 from $150, 12.9x our 2027 EPS estimate, a discount to ZTS's 10-year historical forward P/E average. We cut our 2026 EPS view to $6.92 from $7.03. We keep our 2027 EPS forecast at $7.43. Shares of ZTS are down more than 21% today after the company missed estimates, recording flat organic growth Y/Y, while guidance for the full 2026 for both revenue ($9.680B-$9.960B, 2%-5% organic operational growth) and adjusted EPS ($6.85-$7.00) was cut above expectations, which, in our view, signals that the challenging first quarter environment is likely to persist. The Q1 performance showed significant segment divergence: International business grew 10% organically, while the U.S. segment declined 8%. The Livestock division showed robust 12% organic growth, contrasting with a 4% operational decline in Companion Animal. The U.S. segment saw an 8% revenue decline, with companion animal down 11% due to pet owner price sensitivity, aggressive competitor pricing, and lack of market expansion.

$ZTS

Showing 30361-30380 of 49969

Mining & Metals55d ago

Profound Medical Down 8.5% After Hours as Its Q1 Loss Narrows, Revenue More Than Doubles, Beats Estimates

$PRN.TO$PROF